Cassiere H A, Fein A M
Department of Medicine, SUNY at Stony Brook, NY, USA.
Semin Respir Infect. 1998 Mar;13(1):36-42.
The treatment of hospitalized patients with community-acquired pneumonia (CAP) has traditional been with intravenous antibiotics. More recently, the focus of this antibiotic therapy has been empiric and based on the most likely pathogens in a given patient. The concept of when and how to approach the patient for conversion to oral therapy, known as switch therapy, is now the focus of controversy. Recently, several studies have emerged from the literature that shed some light on the subject of switch therapy for CAP. Although the data are limited at this time, it seems clear that switching to oral antibiotics in selected low-risk patients may be feasible and safe. In this article, we focus on the problem and help formulate a practical approach to switching patients from intravenous antibiotics to oral therapy for CAP.
社区获得性肺炎(CAP)住院患者的治疗传统上一直采用静脉注射抗生素。最近,这种抗生素治疗的重点是经验性的,基于特定患者最可能的病原体。何时以及如何让患者转为口服治疗,即转换治疗的概念,现在是争议的焦点。最近,文献中出现了几项研究,为CAP转换治疗这一主题提供了一些启示。尽管目前数据有限,但在选定的低风险患者中转为口服抗生素似乎是可行且安全的。在本文中,我们关注这个问题,并帮助制定一种将CAP患者从静脉注射抗生素转换为口服治疗的实用方法。